tradingkey.logo
tradingkey.logo
Search

COSCIENS Biopharma Inc

CSCI
Add to Watchlist
2.720USD
0.0000.00%
Close 07/02, 13:00ETQuotes delayed by 15 min
8.64MMarket Cap
LossP/E TTM

More Details of COSCIENS Biopharma Inc Company

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

COSCIENS Biopharma Inc Info

Ticker SymbolCSCI
Company nameCOSCIENS Biopharma Inc
IPO dateDec 19, 1995
CEOMs. Anna Biehn
Number of employees- -
Security typeOrdinary Share
Fiscal year-endDec 19
AddressC/O Norton Rose Fulbright Canada Llp
CityTORONTO
Stock exchangeThe Toronto Stock Exchange
CountryCanada
Postal codeM5K 1E7
Phone18439003201
Websitehttps://www.cosciensbio.com/
Ticker SymbolCSCI
IPO dateDec 19, 1995
CEOMs. Anna Biehn

Company Executives of COSCIENS Biopharma Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--

FAQs

Who are the top five shareholders of COSCIENS Biopharma Inc?

The top five shareholders of COSCIENS Biopharma Inc are: Dr. Ulrich Kosciessa

How many institutions hold shares of COSCIENS Biopharma Inc (CSCI)?

As of 2026Q1, 31 institutions hold shares of COSCIENS Biopharma Inc, with a combined market value of approximately 257.26K, accounting for 8.08% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -38426.00.